RBC Lifts Price Target on Incyte to $61 From $60, Keeps Sector Perform Rating
Incyte Analyst Ratings
BMO Capital Downgrades Incyte to Underperform, Lowers Price Target to $48
Incyte Analyst Ratings
Incyte Corp: Deutsche Bank starts insurance with a holding rating; target price is $55
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
Incyte Analyst Ratings
Incyte's Share Buyback Program: A Buy Rating and Fundamental Value Increase
Incyte's Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63
Truist Securities: Reiterates Incyte's (INCY.US) rating and adjusted from buy to buy rating, target price adjusted from $84.00 to $83.00.
Truist Securities Reiterates Buy on Incyte, Lowers Price Target to $83
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
Incyte Analyst Ratings
BMO Capital Adjusts Incyte Price Target to $52 From $56
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained